---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-003411"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:27:36.352255+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chemomab names Donald Marvin CFO, EVP & COO; outgoing interim CFO stays as advisor

## Summary
- Donald Marvin appointed CFO, EVP, and COO effective November 8, 2021.
- Sigal Fattal's engagement as interim CFO concluded; she will serve as senior consultant to Marvin.
- Marvin receives $460k base salary, 45% bonus potential, $25k signing bonus, and equity (1.5% + 0.5% performance) vesting over 4 years.
- Marvin has over 35 years experience; previous roles include EVP/CFO at Lodo Therapeutics, Chairman/CEO at Concentric, co-founder of Orchid BioSciences.
- CEO Dale Pfost cites Marvin's expertise in building life sciences companies through organic growth and strategic M&A.

## SEC filing metadata
- accession: 0001178913-21-003411
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003411/0001178913-21-003411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003411/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-003411
- JSON: https://secwatch.observer/filing/0001178913-21-003411.json
- Plain text: https://secwatch.observer/filing/0001178913-21-003411.txt

## Key facts
- Executive change
  Donald Marvin was appointed as Chief Financial Officer, Executive Vice President and Chief Operating Officer at Chemomab Therapeutics Ltd..
  - Action: appointed
  - Role: Chief Financial Officer, Executive Vice President and Chief Operating Officer
  source text: On November 8, 2021, the Company issued a press release announcing that, on November 8, 2021, it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003411/0001178913-21-003411-index.htm
- Executive change
  Sigal Fattal departed as Interim Chief Financial Officer at Chemomab Therapeutics Ltd..
  - Action: concluded engagement
  - Role: Interim Chief Financial Officer
  source text: On November 8, 2021, Chemomab Therapeutics Ltd. (the “Company”) and Ms. Sigal Fattal mutually agreed to conclude Ms. Fattal’s engagement as Interim Chief Financial Officer of the Company and its wholly-owned subsidiary Chemomab Ltd. (the “Subsidiary”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003411/0001178913-21-003411-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.